What a peptide is
A protein is a long chain of amino acids. A peptide is the same thing, only far shorter, typically between two and about fifty amino acids. That length determines the function: peptides are short enough to bind a specific receptor and deliver an instruction, but not large enough to serve as structure or as an enzyme.
The body produces peptides constantly. Insulin is a peptide. Growth hormone is a peptide. GLP-1, the hormone that drugs such as Ozempic are built on, is a peptide released by the gut after eating. In that sense peptide therapy is not a novel idea but a long-standing principle in medicine: imitate a message the body already recognises.
Why they are injected rather than swallowed
The digestive system breaks peptides down into amino acids, exactly as it does any dietary protein. Most therapeutic peptides are therefore given by subcutaneous injection. Rybelsus is the exception, and only because of an absorption enhancer that protects semaglutide in the stomach and allows partial uptake. This is why an oral peptide supplement usually does not do what it claims.
Three categories, and they must not be conflated
1. Approved peptides
They have completed full clinical trials, been authorised by a regulator such as the FDA or the EMA, are manufactured under GMP conditions, and are dispensed on prescription with a patient information leaflet. This is where insulin, semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro) and recombinant growth hormone sit. Dosing, side effects and interactions are known and documented.
2. Peptides in clinical trials
Molecules with real human data that are still working through approval. Retatrutide is the prominent current example. They may have an impressive research file, but the regulatory process is not finished, and therefore no licensed manufacturer sells them to the public. The only legal route to receive them is enrolment in a clinical trial.
3. Grey-market peptides
Sold online as "research use only", usually with an explicit statement that they are not for human use. There is no manufacturing oversight, no mandatory purity testing, and no way to know what is in the vial. Some have never been tested in humans at all. This category is the real source of harm.
Retatrutide: what is actually known
Retatrutide is a triple agonist that activates three receptors simultaneously: GIP, GLP-1 and glucagon. That is the mechanistic difference from the current generation. Semaglutide acts on one receptor, tirzepatide on two, and retatrutide adds the glucagon arm, which is associated with increased energy expenditure and with effects on liver fat.
The molecule is being developed by Eli Lilly. In the Phase 2 trial published in the New England Journal of Medicine in 2023, participants lost up to 24.2% of body weight at 48 weeks on the 12 mg dose. The Phase 3 programme, named TRIUMPH, consists of eight pivotal trials running in parallel, enrolling more than 5,800 participants across the weight-management and diabetes indications, plus a separate cardiovascular outcomes trial of roughly 10,000 patients. TRIUMPH-1, an 80-week trial in 2,339 adults with obesity or overweight and at least one weight-related condition but without diabetes, reported that all studied doses of 4 mg, 9 mg and 12 mg met the primary and key secondary endpoints, with clinically meaningful weight reduction alongside improvements in cardiometabolic risk factors. Eli Lilly is expected to submit a Biologics License Application, rather than a New Drug Application since retatrutide is a biologic, around the start of 2027.
Why self-injection is dangerous
The risk is not theoretical, and it does not come only from the molecule itself.
- You do not know what is in the vial. Without pharmaceutical-grade manufacturing there is no assurance of identity, concentration or purity. A powder labelled as a given peptide may contain a different amount, a different molecule, or degradation products.
- Contamination. An injectable preparation must be sterile and free of endotoxins. Powder freeze-dried under uncontrolled conditions does not meet that standard, and bloodstream infection is a severe and fast-moving complication.
- Dosing errors. Grey-market peptides arrive as a powder that has to be reconstituted and calculated. An error in units or in dilution is a tenfold mistake, not a percentage one. This is among the more common reasons people end up hospitalised in this context.
- Nobody is monitoring. Drugs in the GLP-1 family require follow-up of heart rate, blood pressure, liver function, glucose and muscle mass. In self-use there is no testing, no dose titration, and nobody to catch an adverse effect early.
- Interactions and contraindications. In someone with diabetes treated with insulin or a sulfonylurea, adding a GLP-1 agonist can cause hypoglycaemia. The class also carries known contraindications, including a family history of medullary thyroid carcinoma.
- There is no recourse. When something goes wrong with a substance bought online there is no manufacturer, no adverse-event reporting, and no insurance. The emergency department is treating blind.
What you can do instead
Anyone seeking effective metabolic treatment does not need to wait for retatrutide. Semaglutide and tirzepatide are approved, extensively studied, available on prescription with medical supervision, and deliver a substantial share of the benefit. Anyone specifically interested in retatrutide can look into enrolment in an active clinical trial through public trial registries, together with their treating physician.
And for anyone still weighing a grey-market source: the gap between these molecules in the research tables is far smaller than the gap between a regulated product and a powder of unknown origin.
Sources
The information on this site is for educational purposes only and does not constitute medical advice, diagnosis or treatment. Do not start, stop or change any treatment on the basis of this page. Prescription medicines should be taken only under the direction of a physician and with appropriate monitoring. Report side effects to your physician and to your national medicines regulator.